Nimodipine Capsules (marketed as Nimotop).
Nimodipine Capsules (marketed as Nimotop). MedWatch Safety Alert. Rockville, MD: US Food and Drug Administration; January 1, 2006.
This U.S. Food and Drug Administration alert reminds health care professionals that nimodipine should only be administered orally, and that intravenous or parenteral administration can cause serious adverse events.